Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thyroid Cancer Clear all
Approved For Marketing No phase listed Expanded access

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

NCT01683110
View directory record Official record
Conditions
Medullary Thyroid Cancer
Interventions
cabozantinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
U.S. locations
5
States / cities
Stanford, California • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Jul 21, 2026, 4:28 AM EDT
Completed No phase listed Observational Results available

Assess Vitamin D Levels in Those With & Without Thyroid Cancer

NCT00719615
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jul 21, 2026, 4:28 AM EDT
Completed Phase 4 Interventional

Minimizing Narcotic Analgesics After Endocrine Surgery

NCT03469310
View directory record Official record
Conditions
Thyroid Cancer, Thyroid Nodule, Thyroid Neoplasms, Thyroid Goitre, Thyroid Diseases, Parathyroid Diseases, Parathyroid Adenoma, Parathyroid Hyperplasia
Interventions
Acetaminophen 500Mg Cap, Tylenol #3 Oral Tablet, Tramadol
Drug
Lead sponsor
Minerva A Romero Arenas
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Jul 21, 2026, 4:28 AM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Exparel Injection Effect on Postoperative Opioid Usage

NCT04085913
View directory record Official record
Conditions
Thyroid, Parathyroid Adenoma
Interventions
Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine, Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Jul 21, 2026, 4:28 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960
View directory record Official record
Conditions
Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
Interventions
cabozantinib, atezolizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jul 21, 2026, 4:28 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT05355701
View directory record Official record
Conditions
Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions
PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
31
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 4:28 AM EDT
Completed Early Phase 1 Interventional

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

NCT02145143
View directory record Official record
Conditions
Thyroid Carcinoma
Interventions
Vemurafenib, serial 124I PET/CT, thyrotropin alpha
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 21, 2026, 4:28 AM EDT
Completed Phase 2 Interventional

Molecular Testing to Direct Extent of Initial Thyroid Surgery

NCT02947035
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Thyroid lobectomy, Total thyroidectomy with CCND
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Jul 21, 2026, 4:28 AM EDT
Completed Not applicable Interventional

Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer

NCT06073223
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Usual Care, CQUPLE
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 21, 2026, 4:28 AM EDT
Withdrawn Not applicable Interventional

Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound

NCT01225016
View directory record Official record
Conditions
Thyroid Nodules
Interventions
Definity contrast agent
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Jul 21, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

NCT01236547
View directory record Official record
Conditions
Thyroid Gland Anaplastic Carcinoma
Interventions
Intensity-Modulated Radiation Therapy, Paclitaxel, Pazopanib Hydrochloride, Placebo Administration
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
130
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Jul 21, 2026, 4:28 AM EDT
Completed Not applicable Interventional Results available

Reciprocating Medical Devices - a Study of a New Safety Device

NCT00651625
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Trauma, Thyroid Nodule, Cancer
Interventions
Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001, conventional syringe - BD Ref 309604
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jul 21, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Results available

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

NCT01709435
View directory record Official record
Conditions
Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, Thyroid Gland Medullary Carcinoma
Interventions
Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Jul 21, 2026, 4:28 AM EDT
Recruiting No phase listed Observational

Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

NCT03676647
View directory record Official record
Conditions
Thyroid Gland Nodule
Interventions
Diagnostic DNA Methylation Signature
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 21, 2026, 4:28 AM EDT
Completed Phase 1Phase 2 Interventional

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors

NCT04592484
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
CDK-002
Biological
Lead sponsor
Codiak BioSciences
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 21, 2026, 4:28 AM EDT
Terminated No phase listed Observational

ctDNA in Patients With Thyroid Nodules

NCT02778412
View directory record Official record
Conditions
Thyroid Cancer, Thyroid Nodules, Thyroid Adenoma, Thyroiditis
Interventions
Not listed
Lead sponsor
Pathway Genomics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Jul 21, 2026, 4:28 AM EDT
Completed No phase listed Observational

Effect of Childhood Radioiodine Therapy on Salivary Function

NCT02375451
View directory record Official record
Conditions
Xerostomia, Hyperthyroidism, Thyroid Cancer
Interventions
Radioiodine
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Jul 21, 2026, 4:28 AM EDT
Completed Not applicable Interventional Results available

Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation

NCT04129411
View directory record Official record
Conditions
Papillary Thyroid Cancer, Papillary Thyroid Microcarcinoma
Interventions
RFA
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Jul 21, 2026, 4:28 AM EDT
Enrolling by invitation No phase listed Observational

An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

NCT01511393
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma, Weight Management
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
6,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2039
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Jul 21, 2026, 4:28 AM EDT
Terminated Not applicable Interventional Results available

Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma

NCT01974284
View directory record Official record
Conditions
Papillary Thyroid Cancer
Interventions
percutaneous ethanol ablation
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 21, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer

NCT00251316
View directory record Official record
Conditions
Thyroid Cancer, Differentiated Thyroid Carcinoma
Interventions
Lithium Carbonate, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
16 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Jul 21, 2026, 4:28 AM EDT
Terminated Phase 2 Interventional Results available

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

NCT00115739
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Imatinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 21, 2026, 4:28 AM EDT
Available No phase listed Expanded access

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

NCT04566393
View directory record Official record
Conditions
Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation
Interventions
Ulixertinib (BVD-523)
Drug
Lead sponsor
xCures
Industry
Eligibility
12 Years and older
U.S. locations
26
States / cities
Mobile, Alabama • Arroyo Grande, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 21, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin

NCT01182285
View directory record Official record
Conditions
Thyroid Neoplasm
Interventions
Valproic Acid, Liothyronine Sodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Jul 21, 2026, 4:28 AM EDT